Theme: Emerging new technologies in clinical virology

Clinical Virology-2017

Clinical Virology-2017

Sessions & Tracks

Conferenceseries LLC Welcome you to attend the "10th International Congress on Clinical Virology" which is to be transpired on December 4-6, 2017 in Dubai, UAE. The conference focuses on the quintessence Emerging New Technologies in Clinical Virology. Aforesaid Assemblage implores the participation of enthusiasts from all prominent universities, research centers and institutions, microbiologists, mycologists, virologists, students, scholars, diagnostic companies associations and pharmaceuticals to apprise their research cognitions on entire prospects of this dernier cri and illustrating the novel ameliorations and futuristic technologies in operation for the advanced research on viruses.

 General Virology

The Global Virology Market Overview reported an aggregate of $1485.02 million in 2013 and it is estimated to reach $1932.8 million by the year 2018 at a CAGR of about 5.6%. The market growth of virology is remarkable in North America followed by Europe with a predicted significant CAGR growth of about 7% through the forecast period of 2016-2021 due to advancements in the technological development of rapid, futuristic and portable diagnostic tools and tests owing to the ever-improving healthcare infrastructure, convenience and affordability of these diagnostic tests. Hospitals, Research laboratories and other research centers hold 50% stakes in the global virology market and this proclivity is to continue through the year 2025.

Virology  deals with the study of infectious agents like viruses, viral taxonomy, virulence, viral cultures and genetics. It is a significant part of both microbiology and pathology; but being a part of these applied sciences, the discipline of virology is in itself a huge field with its own sub-fields primarily due to advances in the chemical, physical and biological sciences and they gradually became a means to probe various underlying biochemical processes of cells.

Consistently viruses have always been perceived antagonistically as being liable for diseases to be either controlled or annihilated. However, due to advances and understanding of the various processes, it has been found that the viruses also have specific beneficial characteristics that can be exploited for a myriad of objectives.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 

 Viral Pathogenesis, Virulence and their Countermeasures

According to the CTMS (Clinical Trial Management System) which predicted the Global Market Overview, 2014-2019, the market which was priced at $844 million in 2013, will grow at a CAGR of 14% by 2019 and will worth an envisaged $1,848.5 million.

Viral pathogenesis is attaining of the disease in the host by viruses gradually. Factors that determine the transmission, viral multiplication, disease/infection development involve complex, intricate and potent reciprocity between the viral agent and the inclined host. Viruses are capable of causing a disease after contravening the host's elementary physical and natural protective barriers, evading all- local, tissue, and immune defenses that are spread across the host’s body and destroy cells directly or indirectly by the host’s immune and inflammatory responses. Viral pathogenesis is categorized into 7 stages, 1. Transmission  & entry of the virus into the host, 2. Spread of the viral agent in the host, 3. Tropism,  4.  Virulence, 5.  Paradigm of viral infections and diseases , 6.  Host factors,  and  7.  Host defenses.

Infection in a given population are categorized into endemic – in which the infection is present constantly but at a low level at a specific geographical location; epidemic – in which the infection has a greater impact on a population of a specific geographical area and pandemic – in which the infections spread globally and have a higher impact throughout world. Spread of these infections can either be direct – respiratory, water, food and other methods or indirect - involving a vector.

Several quantitative proposals are suggested in terms of epidemiology- such as infectivity, virulence, incidence, disease index, and prevalence. Infectivity is described as the frequency and the rate of the infection transmittance measure after the contact between a virus and an inclined host. Virulence is defined as the aggregate of number of fatalities or extreme diseased cases per total number of cases in the (global) area. Number of new infections within a specified period reflecting the total affected % of population is Incidence. Disease index is the number of indisposed divided by total number of infected people & the rate of cases that exist in a population who are at risk during a pre-defined or the forecasted period is called Prevalence.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 

 Anatomical Pathology

The global Anatomical Pathology and the Tissue Diagnostics market are predicted to grow at a CAGR of approximately 6.97% between the forecast period of 2013 and 2018, to acquire net worth of $3,924.01 Million by 2018.

Anatomical Pathology is typically concerned with the macroscopic, microscopic, biochemical, immunological & molecular probing of organs and tissues to diagnose an infection or a disease. In the recent times, surgical pathology has emerged eminently- we have seen the advancement in form of antecedent histological examination of diseases/affected parts, called autopsy to a more novel and neoteric practice focused on the diagnosis & prognosis to pilot treatment in oncology. Its advanced founder is the Italian scientist Giovan Battista Morgagni. The microscopic examination of probable infected specimens like tissue, cells, bodily fluids and secretions for diagnosis, omission, and scrutinizing of disease in the specimen is all a part of the Anatomical Pathology. The use of novel molecular tests for diagnosing viral infections is on the rise, because of the enhanced sensitivity and rapid result outcome capability of these methods. A myriad of high-end molecular techniques are now available for the identification and quantification of viruses. Molecular diagnostic tools in viral testing have measured a swift progress during recent years and have been adapted by several laboratories due to the ease and convenience in the diagnosis of viruses. These molecular techniques have greatly reduced the use of viral culture based methods and numerous serological assays in diagnosing the infectious viruses in the laboratory. Some of the advanced molecular techniques like Amplified & Non-Amplified Nucleic Acid Techniques, Microarrays, PCR based Techniques, and Target Amplification Techniques are typically employed in diagnosing a viral infection.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 

 Immunohistochemistry

The Global Tissue Diagnostics Market overview was valued at $3,202.5 Million in 2015 and is envisaged to reach $4,471.1 Million by 2020 growing at a remarkable CAGR of about 6.9% in the forecast period of 2015 to 2020. The tissue diagnostics market heralds remarkable and affluent growth potential from 2015 with the major factor that drives the growth is the increasing ubiquity of cancer; while on the other hand, the high degree of consolidation, inflexible regulatory requirements, and dearth of budgets are exorbitating the global growth of this market. The tissue diagnostics categorized into immunohistochemistry (IHC), digital pathology, in-situ hybridization, workflow, and histo-staining. In 2015, the immunohistochemistry accounted for the largest stake in the global tissue diagnostics market with the technology segment of Tissue diagnostics mainly driven by IVD (in vitro diagnostics).

Immunohistochemistry, abbreviated as IHC is a potent method in localizing unambiguous antigens present in the Formalin Fixed, Paraffin Embedded (FFPE) tissues/ specimens predicated on the antigen–antibody interactions. The FFPE technique is extensively used in various research and diagnostics concerning dermatological and histological specimens; IHC’s applications expand continually primarily because of its convenience, reliability, and versatility. In IHC an antigen–antibody complex is explored through the light microscopy. The elementary advantage of IHC over immunofluorescence is the counterstaining which allows the visibility of the morphology of tissue around the antigen with hematoxylin. Results of stained markers are recorded semi-quantitatively and apparently have paramount diagnostic and prognostic implications for skin tumors, lymphoma, and also in the detection of infectious microorganisms in the infected specimens. IHC staining is largely used in the diagnosis of cancerous cells. IHC is also employed in studying and understanding of the distribution and localization of biomarkers and various characteristically expressed proteins in a biological tissue.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 

 Immunopathology

Immunopathology is an immune response concorded when a host is infected by a virus or a viral agent and in often cases can also cause fatalities. The forming of immune complexes in tissues induces inflammation. Circulating immune complexes are usually harmless, but when deposited in tissues can evoke glomerulonephritis, arthritis and vasculitis. Cytotoxic T cells display quite influential effects in vitro, but have very rarely caused acute tissue affliction/damage in vivo. Disruption of cells by antibody-complement complex by antibodies and K cells or even by NK cells portrays a murky role in viral pathology. Delayed hypersensitive T cells are more crucial in immunopathology primarily as they induce inflammation, cause cell infiltration and invoke macrophage-mediated damage to the infected cells. Viral immunopathology is extremely pre-eminent in specific chronic diseases of obscured etiology.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 Diagnostic Virology & Molecular Analysis

Diagnostics market is still incipient and is predicted to reach $3.5 billion by 2020 from the radical value of $1.1 billion, growing at a CAGR of about 20% during the predicted period of 2014 to 2020. The Global Diagnostic Market is categorized based on indication, geography and technology.  The crucial drivers for this market are the discovery and increase in utilization and study of biomarkers and co-development of drugs and various therapies corresponding to these diagnostics. Nevertheless, the costs pertinent with drug development could contravene the growth of diagnostic market. Scope for this market prevails in progressing diagnostics for various infectious and hereditary conditions.

Diagnostic virology is now a crux in pathology and in medical practice. Various approaches are being optimized for the laboratory diagnosis of viral infections, antigen and nucleic acid detection, and serology. The technique of viral culturing is dwindling as novel immunological and molecular tests detect and provide accurate and more rapid results. In the last decade, both qualitative and the quantitative nucleic acid detection techniques has had an extensive impact on viral diagnostics. With advances in self-regulating nucleic-acid sample isolation methods, and real-time detection techniques; a new inception of assays for clinically important viruses is being developed. These technological enhancements potentially generate results within a short time interval. Moreover, the capability of these state-of-the-art technologies characterizes viruses efficiently by the process of sequencing thereby opening new probabilities for further epidemiological studies.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 

 Viral Hepatitis

Due to the extensive infection index of HCV and necessity for the progressive and enhanced therapies, there are a varied of assessments estimating that the global market for HCV is bound to reach $20 billion perennially by the end of this decade.

Hepatitis is a liver inflammation characterized by presence of inflammatory cells in the tissues and can be either acute or chronic, caused by viruses belonging to different families, other than Hepatitis viruses- Cytomegalovirus, Herpes simplex, Yellow fever and Epstein–Barr virus. Transmission of Hepatitis A virus and Hepatitis E virus is by enteral routes while Hepatitis B virus, Hepatitis C virus and Hepatitis D virus is by Parenteral routes.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

Biology of Sexually Transmitted Diseases

The global market for biology of sexually transmitted diseases was valued at $33.3 billion in 2012 and the total market net worth is envisaged to reach $52 billion in 2017 at a CAGR of about 9.3%.

STDs, or rather STIs (Sexually Transmitted Infections) hold a crucial global health prominence because of their overwhelming - emotional, mental and physical impact on women and in infants. Infections with few STDs can accentuate the risk of contracting and transmitting HIV and modify the course of the disease progression. Besides, STDs can also cause chronic health implications, notably in women and infants. Some of the health implications of STDs comprises of cervical cancer, infertility, pelvic inflammatory disease, tubal or ectopic pregnancy and perinatal or congenital infections in infants born to indisposed mothers. A sexually transmitted disease (STD), also called venereal diseases (VD), is a disease which typically transmits through some form of sexual contact, but not necessarily only this mode of transmission. STDs can also be transmitted from infected blood transfusion, from mother to child or also through transmission of bodily fluids, but commonly by sex, especially vaginal intercourse, anal sex and oral sex. As most STIs initially are asymptomatic, which result in an augmented outcome of transmitting the disease to others. Most STIs are treatable or curable; but herpes, hepatitis B, HIV/AIDS, and HPV are only treatable but not curable.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

Hemorrhagic Fever

The global market for Hemorrhagic Fever is envisaged to reach $56 million by 2020 at a remarkable CAGR of about 95.2% in the forecast period of 2015-2020.

Viral hemorrhagic fevers, abbreviated as VHFs are an aggregate of illnesses elicited by four families of viruses – Ebola, Marburg, Lassa fever, and yellow fever viruses. VHFs affect organs, damage blood vessels, and disturbs the body's competence to regulate itself; while some VHFs cause only mild fever, but others, for instance, Ebola or Marburg, are fatal. VHFs are global; while some are specific to the areas where animal vectors are in abundance.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 

Tumor Virology

The global Tumor Virology Market was at its remarkable at $14.99 billion and is envisaged to reach around $35 billion by 2018, developing at a significant CAGR of 18.5% in the predicted period of 2013 to 2018.

Viruses that cause or initiate cancers are called oncoviruses or oncornaviruses- as it was initially thought that only viruses with RNA origin cause cancers- but it now denotes any virus with either a DNA or a RNA genome initiating cancer and is now analogous to tumor virus or cancer virus. Multitude human and animal viruses generally do not evoke cancer because of archaic co-evolution between virus and humans.

World Health Organization's (WHO) -  International Agency for Research on Cancer (IARC), in 2002 reported that approximately 17.8% of all human cancers were infection-initiated, with 11.9% of them being caused by viruses. Although these cancers can be easily prevented through vaccination, but only if diagnosed early with simple blood tests, and are then treated with less-toxic antivirals. In 1908, Vilhelm Ellerman and Olaf Bang from the University of Copenhagen, first established that avian sarcoma leukosis virus can be passed on even after cell-free filtration to susceptible chickens inducing leukemia. In 1910, Peyton Rous at Rockefeller continued Olaf Bang and Vilhelm Ellerman experiment to show filtrated cell-free transmission of sarcoma to susceptible chickens. While in 1964 Anthony Epstein, Bert Achong and Yvonne Barr identified the cardinal human oncovirus from Burkitt lymphoma cells, which was identified as a herpesvirus, and typically called Epstein - Barr virus or EBV.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 

Viral Infections of Oral Cavity

Viral diseases/infections of the oral cavity, oral mucosa and perioral regions are generally encountered by dentists and have not received the required recognition until recently and viruses are both - ulcerogenic and the tumorigenic agents of human oral cavity. The plethora of mammalian viruses in the lesions seen in periodontitis proposes that viruses play a significant role in oral diseases than earlier recognized. One of the most crucial target of oral microbiology in future would be to arbitrate the diversity, magnitude, frequency, pathogenicity, treatment and prognosis of oral viruses and the infections they cause.

Human Herpes virus (HHV) and Human Papillomavirus (HPV) are liable for the most prevalent primary viral infections; with HPV having received crucial scrutiny, as high-risk strains of HPV have been associated with few cases of oral squamous cell carcinoma. However there are numerous other viruses that can cause oral infections in the oral cavity. Some of the viruses that are associated with oral cavity diseases/infections are Cox Sackie Virus, HHV, HPV, Measles Virus, Mumps Virus and Rubella Virus.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 

 Investigational Attempts in Understanding Outbreaks of Viral Infections

Viral Outbreaks generally are pandemic, mostly transmitted via tourists, especially air travelers. These outbreaks have a very serious and hard impact on the global economy. These impacts can be of short term and long term. These impacts sometimes are so severe that it causes about 80% financial impact globally; in the recent Ebola outbreak in 2015, the short term impact was an estimated $359 million in Guinea, Sierra Leone and Liberia alone, which were the severe worst it countries, with the long term impact being $809 million.

Infectious diseases pose a severe threat to global population health and are majorly devastating for the tropical countries as these infectious agents can easily thrive on those climatic conditions. The ease of international travel is one of the primary cause that is liable for transmission of these infectious agents from tropical to temperate and in some cases, also to the polar zones of the world; mainly because of global warming.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 Co-relation of Viral, Fungal and Bacterial Agents in Multi-pathogen Infections

Multiple pathogens sometimes coexist resulting in polyparasitism, which leads to augmented infectivity and diseased condition, modified pathogen load, and emphasis in pathogenesis. For instance, Burkitt's lymphoma is commonly found in regions with high malarial transmittance and it is reported that malaria-induced immune response is linked with the evolution of lymphomas.  These organisms are termed opportunistic infectious agents, and are liable for high morbidity and mortality rates. HIV is one of the opportunistic organisms with high potential to interact with other infectious organisms like parasitic, viral, fungal, and bacterial agents.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 

 Anti-Viral Therapies & Advancements in Vaccines

The global market overview of antiviral drugs, therapies and vaccines is categorized depending on antivirals like Hepatitis-C, HIV , Herpes, Hepatitis-B, Influenza and other antivirals. Some of the crucial aspects that drive the antiviral markets are advances in R&D activities, augmentation in healthcare concerns, awareness and expenditure, increased pervasiveness of ominous viral diseases. According to the market reports, the global antiviral industry- therapies, drugs and vaccines was net worth $4.1 billion for 2013, and it is estimated to reach nearly $6 billion in 2018, growing at a CAGR of 8% in the forecast period of 2013-2018.

Antiviral drugs and vaccines are a class of antimicrobials, which also includes antibiotics and drugs which are solely monoclonal antibodies. Unlike antibacterials, most antivirals are relatively harmless and can be used to treat numerous viral infections.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 Clinical Course of Viral Infections

The Global Infectious Virology Market reported the net worth of $1485.02 million in 2013 and is predicted to reach $1932.8 million by 2018, growing at a CAGR of about 5.6 and is  predicted to grow with a remarkable CAGR growth of about 7% through the forecast period of 2016-2021.

Clinical course of an infection is the behavioral pattern of a virus inside a host after the onset of the infection and how it evolves overtime. It may be per-acute, acute, sub-acute, chronic or intermittent. A deep-rooted knowledge on the clinical Course is essential to understand the disease and the behavioral pattern of the viral agent and to hinder it’s growth which would ultimately lead in hindering the spread of the infection.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 

  Therapeutic Approaches in Viral Infections & Virotherapy

The Universal Therapeutic Industry at a predicted worth of $1485.02 million in 2013 is expected to reach $1932.8 million by 2018 growing at a CAGR of 5.6%.

Virotherapy is a sub-field of Virology and therapeutics, which uses biotechnology as a means to convert viruses into required therapeutic agents by reprogramming the genome and other metabolic pathways of viruses to treat diseases. There are 3 categories of virotherapy as of now:

1. Anti-cancer oncolytic viruses,

2. Viral vectors for gene therapy and

3. Viral immunotherapy.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 Pertinence of Viruses in Nanobiotechnology

Viral Bionanotechnology is still a nascent field, but it is gradually gaining popularity, especially with the automatic parallel formation of viral building blocks is in the hand’s reach after the recent progress of chip-based DNA manipulation to the cell-cultured techniques. The researchers are on the verge of accomplishing the generation of virus-based nanoparticles, multi-layered arrays & hybrid virus networks by incorporation of quantum dots and carbon nanotubes (CNTs). They are also researching the use of virus-like protein cages to form novel materials that can be safely and cost-effectively used for biomedical applications such as biomedical imaging.

Researchers commonly use viruses as the means of vectors to introduce genes into the host cells and typically also as a carrier in gene therapy, after having genetically modified to carry out the activities of a normal human DNA, they also are capable of delivering therapeutic genes to the target cells. Present trends in nanobiotechnology is sure to take virus nanobiotechnology to new heights; Viruses are regarded as organic nanoparticles as their surface has definite tools which are capable of crossing the barriers of the host cells. These impressive and massive approaches of life-sciences in association with chemistry, physics and engineering have become the foundation of modern bio-physical medicine and are opening a wide spectrum of approaches in all these pure and applied fields.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

  Novel Research in Clinical Virology

The global stem cell therapy industry is expected to grow at a CAGR of 39.5% from 2015 to 2020 to reach an estimated $330million by 2020; while the global virology market is expected to reach $1932.8 million by 2018, growing at a CAGR of 5.6%.

Stem cell therapy, one of the widely used therapies and the most researched field in virology uses stem cells to impede a disease or an infection. Bone marrow transplantation is largely executed stem cell therapy. Clinical virology is an intermediary field of medicine comprising of isolating and/or characterizing viruses responsible for various human pathologies by either direct or indirect approaches.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

Veterinary Virology

The global animal healthcare market was esteemed at USD 27,861.2 million in 2013 and is expected to grow at a CAGR of 7.1% from 2014 to 2019, to achieve an expected estimation of USD 41,929.1 million in 2019.

Veterinary virology is the investigation of viruses in animals. It is a critical branch of Veterinary medicine. An emerging virus is a term connected to a new found virus, one that is increasing in occurrence or with the possibility to increment in rate. Zoonotic diseases /contamination's are those which can be actually transmissible from vertebrate animals to humans. Prion disease represents to a group of conditions that influence the nervous system in humans and animals. 

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

 

 

Plant Virology

The agricultural inoculants industry when quoted in appraisal is envisaged to reach about $398.56 million by the year 2019, at a CAGR of about 9.5% from 2014.

The epidemiology of plant virus diseases obligates the cyclical development of virus diseases visceral to plant populace in time and expanse. Tobacco mosaic virus (TMV) is a positive-sense single stranded RNA virus that infects an extensive expanse of plants, principally tobacco and other members of the family Solanaceae. Mycology is the field of biology which accords with the study and research on fungi, constituting their genetic, biochemical properties, taxonomy & their use to humans as a reservoir for tinder, medicine, wine and various entheogens, as well as the perils like poisoning/noxiousity or infection. Viruses exist as obligate intracellular parasites and hence they ought to accomplish unambiguous approaches of transmission, between hosts, in order to endure. 75% of plant viruses have genomes that compose single stranded RNA (ssRNA). 65% of plant viruses have +ssRNA, in essence that they are in the same sense proclivity as messenger RNA but 10% have -ssRNA, in essence they ought to be converted to +ssRNA precedently to being translated. 5% are double stranded RNA and so can be promptly translated as +ssRNA viruses.

 

Related Virology Conferences | Clinical Virology Conferences | Conference Series LLC

6th Clinical Microbiology Conference, October 20-22, 2016 Rome, Italy; International Conference and Expo onIndustrial Microbiology August 01-03, 2016 Frankfurt; European Microbiology Conference August 04-06, 2016 Frankfurt, Germany; 2nd International Conference on Parasitology August 01-03, 2016 Manchester, UK; International Conference on Mycology September 12-14 San Antonio, USA; 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016) June 16-20, 2016 Boston, USA; Anaerobe 2016 July 11-14,2016 Nashville, USA; Microbe 2016, September 23-25, 2016 Sheffield, UK

Entrepreneur Investments Meet:   Description

A key ingredient in successful entrepreneurship is self-knowledge. (Water Microbiology-2016) aims to bring together all existing and budding bio entrepreneurs to share experiences and present innovations and challenges in microbiological community. Each year, over a million companies are started in the world with about 5–10 of them classified as high technology companies. Turning ideas into business ventures is tricky and the opportunity-recognition step is critical in new venture creation. This gestalt in the entrepreneur's perception of the relationship between the invention and final product is refined into a business model that describes how the venture will make money or provide an appropriate return to the potential investors. Biological science is complex and rapidly changing and requires a specialized knowledge to understand the value of the innovation and its competitive position in the industry. Although life scientists are typically the founders of biotech companies, studies have shown that the most successful high tech startups are founded by a team of two to three individuals with mixed backgrounds, substantial industry experience and a very clear market and product focus at founding. This three day community-wide conference will be a highly interactive forum that will bring experts in areas ranging from structural microbiology to signaling pathways to novel therapeutic approaches to the scientific hub. In addition to our outstanding speakers, we will also showcase short talks and poster presentations from submitted abstracts. The speakers will discuss how microbes can be engineered to report using computational inputs from their local environment. This session will include combined efforts of cutting edge synthetic biology research to highlight the current state, challenges and future of engineered microbial communities.

 





Market Analysis Report

Clinical Virology-2017 welcomes attendees, presenters, and exhibitors from all over the world to Atlanta. We are delighted to invite you all to attend and register for the 10th International Congress on Clinical Virology" December 4-6, 2017 in Dubai, UAE.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Clinical Virology-2017, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Clinical Virology-2017 organizing committee are looking forward to meet you in Dubai, UAE.

For more details please visit- www.clinicalvirology.conferenceseries.com/

Importance & Scope:

Clinical or medical virology is a branch of clinical pathology which consists in isolating and/or in characterizing one or several viruses responsible for some human pathology by various direct or indirect techniques (cellular Cultures, serology, biochemistry, molecular biology). It also consists in proving the absence of resistance of viruses in treatment antiviral by viral genome sequencing to adapt antiviral therapeutics at best. Clinical Virology-2017 conference is bringing experts from the field of virology for discussion of the latest advances and ideas and to stimulate interdisciplinary interactions.

 

 





About Conference

Conference Series LLC welcomes you to attend the "10th International Congress on Clinical Virology" during December 4-6, 2017 at Dubai, UAE. This conference is focusing on the theme “Emerging new technologies in clinical virology”. The conference invites participants from all leading universities, research institutions, microbiologists, virologists and diagnostic companies to share their research experiences on all aspects of this rapidly expanding field and thereby, providing a showcase of the recent advancements and technologies being used and developed for the research on viruses.





Past Conference Report

Virology-2015

Virology-2015 Report

Thanks to all of our wonderful speakers, conference attendees and Exhibitors, Virology-2015 Conference was our best ever!

5th World Congress on Virology conference, hosted by the OMICS International was held during December 07-09, 2015 Atlanta, USA at Hilton Atlanta Airport Hotel, Atlanta, USA with the theme “Anti-Viral Immunity and Countermeasures to Control Disease Pathogenesis”. Benevolent response and active participation was received from the Editorial Board Members of OMICS Group Journals as well as from the Scientists, Doctors, Professors, Virology Lecturers, Pharmaceutical Industries, Biotech Industries, Researchers and Students from the fields Virology -2015, who made this event successful.

The meeting was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

General Virology and Basic Science

Clinical and Neuro Virology

Respiratory and Emerging/Re-emerging Viruses

Agriculture and Plant Virology

Therapeutic Approaches and Targets for Viral Infections

Veterinary Virology

Viral Immunology

Viral Hepatitis

HIV and Other Retroviral Diseases Affecting Afro-Asian Continents

Organ specific Cancer and Tumor virology

Regulatory and Economical Aspects in Virology

Recent Advances in Drug Discovery

Current Focus in Virology Research

The conference was initiated with a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The list included:

Dharam Ablashi
HHV-6 Foundation,KHG fiteBac® Technology,USA

Chil Yong Kang
Western University,Canada

Ting-Chao Chou
PD Science LLC,USA

Ronald Moss
Ansun Biopharma,USA

Shahana Choudhury
Meharry Medical College,USA

Farshad Guirakhoo
GeoVax,Inc, USA

Michael W Washabaugh
MedImmune, USA

Sang-Moo Kang
Georgia State University, USA

Bala Chandran
Rosalind Franklin University of Medicine and Science, USA

Hye Kyung Chung
Advanced BioScience Laboratories, USA

Miguel Angel Mendoza Catalan
Autonomous University of Guerrero, Mexico

Brian L Pearlman
Atlanta Medical Center, USA

Anjali Joshi
Texas Tech University Health Sciences Center, USA

Hua Zhu
Rutgers University, USA

Khaled Barakat
University of Alberta, Canada

Kylie Wagstaff
Monash University, Australia

Qian Yang
Nanjing Agricultural University, China

Souvik Ghosh
Ross University School of Veterinary Medicine, St. Kitts, West Indies

Masaaki Kawano
Saitama Medical University, Japan

Abdelouaheb Benani
Pasteur Institute of Morocco, Morocco

Vladimir Zajac
Cancer Research Institute, Slovak Academy of Sciences, Russia

Todd E Bell
Texas Tech University Health Science Center, Amarillo, USA

Mohamed El Zowalaty
Biomedical Research Center, Qatar University, Doha, Qatar

Nada Melhem
American University of Beirut, Lebanon

Mohammad Intakhab Alam
Zirve University,Turkey

Sita Awasthi
University of Pennsylvania, USA

With the grand success of Virology-2015, OMICS Group is proud to announce the " 7th World Congress on Clinical Virology” to be held during October 13-14, 2016 Manchester,UK.

For more information please visit: www.clinicalvirology.conferenceseries.com/

Virology-2014

The 4th World Congress on Virology, hosted by the OMICS International was held during October 06-08, 2014 at Hilton San Antonio Airport Hotel, San Antonio, USA with the theme “Anti-Viral Immunity and Counter measures to Control Disease Pathogenesis". Benevolent response and active participation was received from the Editorial Board Members of OMICS International Journals as well as from the scientists, engineers, researchers, students and leaders from the fields of Virology, who made this event successful.

The meeting was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

General viral science

Viral Breakout: Preventions and Measures

 Human Viral Diseases Affecting Afro-Asian Continents

 Organ Specific Cancers and Tumours Virology

 Respiratory and Vector Borne Diseases

 Therapeutic Approaches and Targets for Viral Infections

 Viral Hepatitis and Viral Immunology

  Neurological Infections Associated with Viruses

  Agriculture and Plant Virology

  Animal Virus and Bacteriophages

  Recent Advances in Drug Discovery

  Current Focus in Virology Research

The conference was initiated with opening remarks by Dr. Sita Awasthi followed by Keynote lecture and plenary lectures byDr.John Edwar Collony, Institute of Molecular and Cellular Biology, USA, Dr.Neal S Rote, Case Western Reserve University, USA,Dr. James Mahony, Mc Master Unviersity, Canada.

Virology-2013

The 3rd World Congress on Virology took place in Baltimore, USA on November 20-22, 2013.The conference was titled: “Exploring Novel Approaches in Virology” and hosted by the OMICS International. Generous response and active participation was received from the Editorial Board Members of OMICS International Journals, Organizing Committee Members, scientists, researchers, clinical experts and leaders from the field of Virology.The conference was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

HIV Vaccines

Therapeutic Approaches and Targets for Viral Infections

 Human Viral Diseases Affecting Afro-Asian Continents

 HIV and Other Retroviruses

 Respiratory Viral Infections

 Viral Hepatitis

 Viral Immunology

  Agriculture and Plant Virology

  Recent Advances in Drug Discovery

The conference paved its way by the introductory speeches from Honourable guests and members of the Keynote forum such as Dr. Marc H.V. Van Regenmortel, University of Strasbourg, France, Dr. Ruth M. Ruprecht, Texas Biomedical Research Institute, USA, Dr. Jean-Marie Andrieu, University of Paris-Descartes, France,Dr. Hiroshi Ohrui, Yokohama College of Pharmacy, Japan.

Virology -2012

The 2nd World Conference on Virology, hosted by the OMICS International was held during August 20-22, 2012 at Embassy Suites, Las Vegas, USA. Generous response and active participation was received from the Organizing Committee & Editorial Board Members of OMICS International Journals as well as from scientists, researchers and leaders from pharma, government organizations and students who made this conference as one of most successful and productive events in 2012 from OMICS International.The conference was carried out through various sessions, in which the discussions were held on the following scientific tracks

HIV Research

Agriculture Virology

Epidemic studies

Animal Virology

Influenza Viruses

Drug discovery program

Hepatitis Research

Anti Viral and Retro-viral drugs and therapy

Tumor Virology

Anti Viral Vaccine development

The conference was initiated with opening remarks by Dr. Pawel Ciborowski followed by Keynote lecture by Dr. N. J. Krogan University of California. Keynote forum included Fatah Kashanchi, George Mason University, USA; Pooja Jain, Drexel University College of Medicine, USA; Ralph Tripp, University of Georgia, USA.

 

 


Past Reports  Gallery  



Past Conference Report

Virology-2014

Virology-2014 Report

Thanks to all of our wonderful speakers, conference attendees and Ad sponsors, Virology-2014 Conference was our best ever!

The 4th World Congress on Virology, hosted by the OMICS Group was held during October 06-08, 2014 at Hilton San Antonio Airport Hotel, San Antonio, USA with the theme “Anti-Viral Immunity and Counter measures to Control Disease Pathogenesis". Benevolent response and active participation was received from the Editorial Board Members of OMICS Group Journals as well as from the scientists, engineers, researchers, students and leaders from the fields of Virology, who made this event successful.

The meeting was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

  • General viral science
  • Viral Breakout: Preventions and Measures
  • Human Viral Diseases Affecting Afro-Asian Continents
  • Organ Specific Cancers and Tumours Virology
  • Respiratory and Vector Borne Diseases
  • Therapeutic Approaches and Targets for Viral Infections
  • Viral Hepatitis
  • Viral Immunology
  • Neurological Infections Associated with Viruses
  • Agriculture and Plant Virology
  • Animal Virus
  • Bacteriophages
  • Recent Advances in Drug Discovery
  • Current Focus in Virology Research

The conference was initiated with a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The list included:

  • John Edwar Collony, Institute of Molecular and Cellular Biology, USA
  • Neal S Rote, Case Western Reserve University, USA
  • Ralph A Tripp, University of Georgia, USA
  • Sita Awasthi, University of Pennsylvania, USA
  • James Mahony, Mc Master Unviersity, Canada
  • Julia Hillard, Georgia State University, USA

With the grand success of Virology-2014, OMICS Group is proud to announce the "5th World Congress on Virology" to be held duringDecember 07-09, 2015 Atlanta, USA

For more information please visit: http://virology.omicsgroup.com/


Past Reports  Gallery  



Past Conference Report

Virology-2011
Virology-2011 Report
The International Conference & Exhibition on Virology, hosted by the OMICS Groupwas held from September 5-7 2011, in Baltimore, USA. Generous response and active participation received from the Editorial Board Members of OMICS Group as well as from Virologists, Researchers and leaders from pharma, government organizations. Also principal investigators from FDA, NCI & NIH helped in making this meeting a grand success. 

The programme was a rich mix of formats ranging from plenary sessions featuring many well-known and thought provoking key note speakers to intense, highly interactive discussion sessions. The scientific program also helped to pave a way to gather visionaries through the research talks and presentations and put forward many thought provoking strategies inVirology

The conference carried out through various sessions, in which the discussions were made on the following tracks 

  • Viral Genomics and Proteomics
  • Antiviral Vaccine Development
  • HIV Associated Diseases
  • Clinical Viral Diagnostics
  • Gene Therapy
  • Agriculture and Plant Virology
  • Tumour Virology and Immunology
  • Pediatric Viral Diseases
  • Veterinary Viral Genomics and Proteomics
  • Regulatory and Economical Aspects in Virology

The conference benefited from a series of keynote addresses by well-known speakers Dr. Pawel Ciborowski University of Nebraska Medical Center, USA, Dr. Subhash DhawanFood and Drug Administration, USA, Mr. Gary Alan Flory Virginia Department of Environmental Quality, USA, Dr. Wei Wang US Food and Drug Administration, USA, Dr. Ting Chao Chou Memorial Sloan-Kettering Cancer Center, USA, Dr. Harold C. SmithUniversity of Rochester School of Medicine and Dentistry, USA, Dr. David Jans Monash University, Australia. 

All the above mentioned Keynote speakers have given their energetic contribution towards all the sessions with enthusiastic discussions and following recommendations, 

  • Irresistible strategies and approaches on HIV & Vaccine development from more than 50 eminent scientists who are majorly doing research on Virology
  • Panel discussions that were conducted at the Conference helped the scientific community in creating new drugs to inflate the human life.

As a result of all contributions, OMICS Group produced the following publications: Journal of AIDS & Clinical Research, Journal of Antivirals & Antiretrovirals 

We are also grateful to other speakers and company representatives, who supported the conference by facilitating the discussion forums. We are thankful to the advice on the agenda, and guidance by our organising committee members . We are grateful to our sponsors for their generous sponsorship of the event. 

 


Past Reports  Gallery  



Past Conference Report

Virology -2012
 
Virology-2012 Report
The 2nd World Conference on Virology, hosted by the OMICS Group was held during August 20-22, 2012 at Embassy Suites, Las Vegas, USA. Generous response and active participation was received from the Organizing Committee & Editorial Board Members of OMICS Group Journals as well as from scientists, researchers and leaders from pharma, government organizations and students who made this conference as one of most successful and productive events in 2012 from OMICS Group

The conference was carried out through various sessions, in which the discussions were held on the following scientific tracks
  • HIV Research
  • Agriculture Virology
  • Epidemic studies
  • Animal Virology
  • Influenza Viruses
  • Drug discovery program
  • Hepatitis Research
  • Anti Viral and Retro-viral drugs and therapy
  • Tumor Virology
  • Anti Viral Vaccine development
The response to 2nd World Congress on Virology was huge and was attended by about 200 delegates representing 25 countries from different parts of the world. 

The conference was initiated with opening remarks by Dr. Pawel Ciborowski followed by Keynote lecture by Dr. N. J. Krogan University of California. Keynote forum included Fatah Kashanchi, George Mason University, USA; Pooja Jain, Drexel University College of Medicine, USA; Ralph Tripp, University of Georgia, USA. 

All the above mentioned keynote speakers gave their energetic and fruitful contributions at2nd World Congress on Virology. Day 1 and Day 2 included exhaustive poster presentations by young researchers and veterans.

Moreover, Workshop: NIH Grantsmanship by Fatah Kashanchi, George Mason University, USA and Workshop on High Throughput Screening and Assay Development by G. Sitta SittampalamNational Institutes for Health (NIH), USA was organized in the Conference. Simultaneously, Editorial Board meeting and B2B sessions between happening scientists and individuals from Business Community took place. 

All accepted abstracts have been indexed in OMICS Group Journal of Antiviral & Antiretroviral as a special issue. The theme of this Conference was "Innovations and Therapeutic approaches in Virology". Based on this, speaker's discussions included many recommendations. 

We are also obliged to various external experts, company representatives and other eminent personalities who supported the conference by facilitating the discussion forums. Our sincere thanks to Organizing Committee Members Pawel S Ciborowski, University of Nebraska Medical Center, USA; Harold C Smith, University of Rochester, USA; Fatah Kashanchi, George Mason University, USA; Pooja Jain Drexel University College of Medicine, USA;David Jans, Monash University, Australia for their gracious presence, support and assistance towards 2nd World Congress on Virology, and with their unique feedback, OMICS Group would like to announce the "3rd World Congress on Virology" to be held in 2013. 
 

 


Past Reports  Gallery  



Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date December 4-6, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Conferenceseries Destinations